Akari Share Price
NASDAQ: AKTX | Mega Cap | HealthcareAkari Stock Performance
Akari Share Price Chart
Akari Quarterly Profit & Loss
All figures in USD
Akari Annual Profit & Loss
All figures in USD
Akari Balance Sheet
All figures in USD Million
Akari Cash Flow
All figures in USD Million
Corporate Actions
About Akari
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $8.18 | $7.17 | -13.20% |
Oct 2026 | $9.64 | $8.26 | -14.85% |
Sep 2026 | $10.31 | $9.70 | +8.14% |
Aug 2026 | $7.54 | $8.97 | +11.58% |
Jul 2026 | $10.64 | $8.04 | -19.77% |
Jun 2026 | $15.76 | $10.02 | -38.15% |
May 2026 | $5.50 | $16.20 | +199.45% |
Apr 2026 | $5.46 | $5.41 | +4,334.43% |
Mar 2026 | $0.23 | $0.12 | -48.52% |
Feb 2026 | $0.24 | $0.24 | -5.95% |
Jan 2026 | $0.28 | $0.25 | -11.58% |
Dec 2025 | $0.45 | $0.28 | -38.18% |